Find Clinical Trial

Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in non-depressed out-patients with severe Generalized Anxiety Disorder. A 12-week randomised, double-blind, versus escitalopram, 2-arm parallel groups, international multicenter study with a 9-month extension period


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

Active substance/
Medical device

S020098, AGOMELATINE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS020098
Protocol CodeCL3-20098-089
EudraCT Code2012-003699-37


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility